Ligand Pharmaceuticals Incorporated — FY2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. The filing also reports fourth-quarter results. Ligand is a biopharmaceutical licensing and technology company whose revenue is principally royalties, Captisol material sales, and license and milestone payments. Its partners generally fund development and commercialization.
Financial performance and liquidity
| Metric | FY2016 | FY2015 |
|---|---|---|
| Total revenue | $109.0 million | $71.9 million |
| Royalties | $59.4 million | $38.2 million |
| Material sales | $22.5 million | $27.7 million |
| License, milestone and other revenue | $27.0 million | $6.1 million |
| Operating income | $43.9 million | $27.3 million |
| Net income (loss) | $(1.6) million | $229.8 million |
| Net cash from operating activities | $63.0 million | $41.7 million |
- Revenue grew 52%, chiefly from increased Promacta and Kyprolis royalties and OMT license fees, plus an Evomela approval milestone. Promacta royalties were $43.0 million and Kyprolis royalties $12.1 million.
- Operating expenses rose 46% to $65.1 million. Higher amortization and R&D costs largely reflected the OMT acquisition; R&D expense was $21.2 million, up from $11.0 million.
- FY2016 included a $23.1 million loss from Viking, including a $7.4 million impairment charge and dilution-related loss. Net loss also reflected a $10.3 million income tax expense. FY2015 net income was unusually elevated by a $192.1 million tax benefit, so headline net income comparisons are not representative of underlying operating trends.
- Fourth-quarter revenue was $38.2 million versus $21.2 million in Q4 2015. Q4 2016 continuing-operations loss was $3.1 million; net loss was also $3.1 million. The quarterly table’s reported Q4 basic and diluted per-share figures appear inconsistent with the reported net loss; the filing text does not provide a clear reconciled value.
- Cash and cash equivalents were $18.8 million and short-term investments $122.3 million at year-end. Working capital was negative $64.1 million, principally reflecting the convertible notes’ current classification. Total assets were $601.6 million.
- The company had $245.0 million principal amount of 0.75% convertible senior notes due 2019; $212.9 million was presented as current carrying value, with a further $29.6 million equity component classified as mezzanine equity. The notes became current because the stock-price conversion condition was met. Management said it believed early conversion was remote and expected available funds and operating cash generation to meet anticipated needs, while acknowledging no assurance.
Material changes and business developments
- Ligand acquired Open Monoclonal Technology (OMT), adding the OmniAb antibody-discovery platform and partner programs. Consideration was $173.4 million, comprising $96.0 million cash and approximately $77.4 million in stock.
- Ligand paid $17.5 million for economic rights to CorMatrix medical-device programs and recorded $1.5 million of CorMatrix royalty revenue in 2016.
- Promacta and Kyprolis royalties increased year over year; Captisol material sales declined 19% as partner purchase timing shifted. Ligand reported that a small number of partners accounted for substantial revenue, with two partners contributing 41% and 14% in 2016.
- Partners reported FDA approval of Evomela and Carnexiv, and a European approval expanding Promacta use in children. Melinta submitted an NDA for IV Baxdela. Ligand’s internal LGD-6972 program entered Phase 2 for type 2 diabetes; management expected results in Q3 2017.
Outlook, risks and unusual items
- Management gave no numerical revenue or earnings guidance. It expected cash generation to grow with royalties, Captisol sales, approvals, new licenses and milestones, and stated existing funds and financing access should cover anticipated requirements.
- Ligand expects ASC 606 adoption in 2018 to materially affect reported results, principally by recognizing royalties one quarter earlier and potentially accelerating certain milestone revenue.
- Key business exposures include reliance on Promacta, Kyprolis and Captisol revenue; dependence on a sole Captisol supplier, Hovione; partner termination rights; drug-development and regulatory uncertainty; patent challenges and generic competition; and the risk that partner programs fail or are discontinued. Merck halted a Phase 3 verubecestat trial in mild-to-moderate Alzheimer’s disease for futility; a separate prodromal Alzheimer’s study was continuing, with results expected in 2019.
- The company restated prior financial statements, including 2015 and the first two quarters of 2016. Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end due to material weaknesses, including controls over tax accounting for complex transactions and convertible-note presentation. Ernst & Young issued an adverse opinion on internal control, while expressing an unqualified opinion on the 2016 financial statements.
- A shareholder class action filed in November 2016 relates to the restatement; Ligand said it would defend the case. A separate securities case from 2012 remained on appeal. The Par NOXAFIL-IV patent dispute was settled confidentially in 2016.
Important facts for investors to verify
- Whether recurring royalty growth from Promacta and Kyprolis can offset variability in Captisol orders and license or milestone revenue, and the degree of customer concentration.
- The timing and cash settlement terms of the $245.0 million 2019 notes, including potential conversion, redemption and dilution exposure.
- Progress in remediating the reported material weaknesses and any subsequent restatements or changes in audit/control assessments.
- Integration and returns from the OMT acquisition and CorMatrix rights, including future licensing, commercial revenue and impairment risk.
- Partner development, regulatory and commercialization updates for major programs, including LGD-6972, sparsentan, SAGE-547 and the continuing verubecestat study.